Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Financing › Details

GeneWake–Germany (govt): grant, 201304– 2-year BMBF grant €200k to develop pharmacodx test for prostate + bladder cancer within m4 Initiative


Period Period 2013-04-01 ï¿½ 2015-03-31
Region Region Germany
Organisations Money taker GeneWake GmbH
  Group R-Biopharm (Group)
  Money source BMBF (Federal Ministry for Education and Research) (DE)
  Group Germany (govt)
Products Product pharmacogenomic/pharmacogenetic cancer test
  Product 2 cancer test, pharmacogenomics

GeneWake GmbH. (4/1/13). "Press Release: Comprehensive Biomarker Screening for the Individual Treatment of Prostate and Bladder Cancer".

Clinical investigation of innovative biomarker diagnostics of blood and urine

On 1st of April, 2013 GeneWake started a study focusing on the development and clinical examination of a molecular and non-invasive diagnostics of prostate and bladder cancer. The project is funded by the German Federal Ministry of Education and Research (BMBF) under the 'm4 - Personalised Medicine and Targeted Therapies' initiative of the Munich Biotech Cluster.

Modern cancer treatment is based increasingly on a tailored therapy for the individual patient. This is attributable to the fact that no one single tumor resembles another in its molecular structure and therefore reacts differently to cancer therapeutics. In prostate cancer and also in bladder cancer, some genes (so called biomarkers) are frequently affected by changes. Some of these changes can, for example, induce resistance to common chemotherapeutics.

The problem in analyzing single biomarkers is, that only a certain percentage of tumors are affected by this change. The investigation of all relevant biomarkers for mutations is too expensive and time-consuming. For these reasons, GeneWake pursues an approach based on the simultaneous investigation of a complete tumor-specific set of biomarkers, which are analyzed on the level of gene products (gene expression).

Dr. Robert Loewe, the CEO of GeneWake, specifies the aim of the study: "The expression analysis of multiple genes which are relevant for a given type of tumor enables us to obtain a clearer and more comprehensive picture of the factors that cause or contribute to tumor growth. Using our technique, resistances or targets for therapeutic agents can be detected. Additionally, an early detection of cancer or an assessment of the prognosis is conceivable."

Dr. Sabine Ott, head of business development of the company, explains: "This innovative diagnostic approach could enable, for example, therapy monitoring of patients with prostate or bladder cancer. Regular molecular blood and urine analyses over the course of a therapy could examine the efficacy of the current treatment. An insufficient effectiveness could be detected at an early stage, even prior to imaging methods, and improved by an immediate therapy adjustment based on the results of the gene expression analyses."

With this project, which is conducted in close cooperation with the Urology Department of the Ludwig-Maximilian-University Hospital in Munich, Director: Prof. Christian Stief, GeneWake will contribute to an affordable individualizd treatment of prostate and bladder cancer.

The project "tumor marker diagnostics for the personalized treatment of prostate and bladder cancer" runs for two years and is supported by the Federal Ministry of Education and Research (BMBF) with around 200.000 €.

GeneWake is a pharmacogenomics company focussed on biomarker analysis for the field of oncology. Proprietary bioinformatical algorithms based on the company's thorough knowledge in oncology pathways enable high quality detection of new biomarkers. GeneWake realizes a personalized cancer treatment by offering targeted expression analyses of relevant biomarker panels or single biomarkers in tumor tissue and circulating tumor cells for patient stratification or therapy tracking. Additionally, GeneWake provides the development of innovative diagnostic kits or molecular techniques and services like next generation sequencing, mutation detection, SNP genotyping, multiplex PCR and immunohistology.


Sabine Ott, PhD
GeneWake GmbH
Floriansbogen 2-4
82061 Neuried

About the leading-edge cluster programme 'm4 - Personalised Medicine and Targeted Therapies'

This project is funded by the program 'm4 - Personalised Medicine and Targeted Therapies' for which the Munich Biotech Cluster was awarded 'Leading-Edge cluster status' by the German Federal Ministry of Research and Education (BMBF) in 2010. For a 5-year period, the program is funded with EUR 40 million from the BMBF, which are complemented by EUR 40 million from the participating companies in more than 40 cooperative R&D projects from industry and scientific institutions. The Bavarian Ministry of Economic Affairs, Infrastructure, Transport and Technology supports the cluster management agency BioM and particular components of the concept with an additional EUR 12 million. For more information visit

Record changed: 2017-04-02


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for R-Biopharm (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top